Tumor Immunotherapy in Melanoma
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 9 (5), 307-311
- https://doi.org/10.2165/00128071-200809050-00004
Abstract
The incidence of melanoma has been steadily increasing over the last 3 decades. Currently, there are several approved treatments for metastatic melanoma, including chemotherapy and biologic therapy...Keywords
This publication has 31 references indexed in Scilit:
- Chemotherapy for metastatic melanomaCancer, 2007
- Regulation of gene expression in melanoma: New approaches for treatmentJournal of Cellular Biochemistry, 2004
- Exposure of Melanoma Cells to Dacarbazine Results in Enhanced Tumor Growth and Metastasis In VivoJournal of Clinical Oncology, 2004
- Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communicationOncogene, 2001
- Paclitaxel Induces Prolonged Activation of the Ras/MEK/ERK Pathway Independently of Activating the Programmed Cell Death MachineryJournal of Biological Chemistry, 2001
- Classical chemotherapy for metastatic melanomaClinical and Experimental Dermatology, 2000
- Expression of interleukin-8 detected byin situ hybridization correlates with worse prognosis in primary cutaneous melanomaThe Journal of Pathology, 1999
- Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour loadMelanoma Research, 1995
- Analysis ofras mutations in human melanocytic lesions: activation of theras gene seems to be associated with the nodular type of human malignant melanomaZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- RAS Mutations in Human Melanoma: A Marker of Malignant ProgressionJournal of Investigative Dermatology, 1994